Director, Clinical Research — RNAi Therapeutics Lead (Phase 2–3)

Alnylampharmaceuticals

Cambridge, Maidenhead

On-site

GBP 190,000 - 258,000

Full time

14 days+

A complete application in a minute

Tailored resume and cover letter, ready to send.

Get past ATS filters

Job summary

Alnylam Pharmaceuticals in Cambridge, UK seeks an imaginative physician drug developer to lead RNAi programs across neurology and hematology. The Director, Clinical Research, will drive the plasminogen program from Phase 2 to Phase 3, providing clinical leadership and oversight to global regulatory strategies.

You will report to the program strategy lead, supervise trial conduct and safety, and engage with external experts at regulatory and scientific meetings.

Qualifications

  • MD with strong research background or MD PhD with best-in-class clinical and/or research training.
  • Board Certification (or equivalent) in neurology is desirable.
  • 3+ years industry experience or equivalent clinical academic research experience.
  • Sound scientific and clinical judgment.
  • Familiarity with clinical research concepts, biostatistics, regulatory guidelines.

Responsibilities

  • Be the strategic leader providing a strong, clear voice for the clinical program.
  • Develop creative but realistic drug-development approaches and lead clinical efforts toward global regulatory approvals.
  • Oversight of trial conduct and safety.
  • Collaborate with Preclinical, Regulatory Affairs and Medical Affairs for integrated development plans.
  • Supervise major written deliverables (regulatory submissions, articles, abstracts) and sign-off protocols and ICFs.
  • Influence internal and external audiences in a high-impact, visible fashion.

Skills

MD with research background
Neurology board certification
Leadership in matrix environment

Education

MD or MD-PhD

Job description

Alnylam Pharmaceuticals in Cambridge, UK seeks an imaginative physician drug developer to lead RNAi programs across neurology and hematology. The Director, Clinical Research, will drive the plasminogen program from Phase 2 to Phase 3, providing clinical leadership and oversight to global regulatory strategies.

You will report to the program strategy lead, supervise trial conduct and safety, and engage with external experts at regulatory and scientific meetings.

Get your free, confidential resume review.

or drag and drop your file here.

Similar jobs

Similar jobs worth comparing

Strategic Director, Clinical Research — RNAi Therapeutics
Strategic Director, Clinical Research — RNAi Therapeutics

Alnylam • Maidenhead

On-site
GBP 90,000 - 180,000
Director, Clinical Research — RNAi Therapeutics Lead
Director, Clinical Research — RNAi Therapeutics Lead

Alnylam Pharmaceuticals, Inc. • Maidenhead

On-site
GBP 190,000 - 258,000
Director, Clinical Research- Benign Hematology
Director, Clinical Research- Benign Hematology

Alnylam • Maidenhead

On-site
GBP 90,000 - 180,000
Director, Clinical Research- Benign Hematology
Director, Clinical Research- Benign Hematology

Alnylampharmaceuticals • Cambridge, Maidenhead

On-site
GBP 190,000 - 258,000
Executive Director, Clinical Research - Neurodegeneration
Executive Director, Clinical Research - Neurodegeneration

Alnylam Pharmaceuticals, Inc. • Maidenhead

Hybrid
GBP 189,000 - 303,000
Hybrid Exec Director, Clinical Research - Neurodegeneration
Hybrid Exec Director, Clinical Research - Neurodegeneration

Alnylam Pharmaceuticals, Inc. • Maidenhead

Hybrid
GBP 189,000 - 303,000
Sr. Manager, Regulatory Affairs
Sr. Manager, Regulatory Affairs

Alnylam Pharmaceuticals, Inc. • Maidenhead

On-site
GBP 90,000 - 120,000
Senior Manager, R&D Quality Assurance
Senior Manager, R&D Quality Assurance

Alnylam Pharmaceuticals, Inc. • Maidenhead

Hybrid
GBP 110,000 - 150,000
Senior Manager, R&D Quality Assurance
Senior Manager, R&D Quality Assurance

Alnylam • Maidenhead

Hybrid
GBP 95,000 - 130,000
Associate Director, Biostatistics
Associate Director, Biostatistics

Alnylam Pharmaceuticals, Inc. • Maidenhead

Hybrid
GBP 120,000 - 160,000